Sex Differences and the Role of Estradiol in Mesolimbic Reward Circuits and Vulnerability to Cocaine and Opiate Addiction

Saurabh S. Kokane and Linda I. Perrotti*

Department of Psychology, University of Texas at Arlington, Arlington, TX, United States

Although both men and women become addicted to drugs of abuse, women transition to addiction faster, experience greater difficulties remaining abstinent, and relapse more often than men. In both humans and rodents, hormonal cycles are associated with females’ faster progression to addiction. Higher concentrations and fluctuating levels of ovarian hormones in females modulate the mesolimbic reward system and influence reward-directed behavior. For example, in female rodents, estradiol (E2) influences dopamine activity within the mesolimbic reward system such that drug-directed behaviors that are normally rewarding and reinforcing become enhanced when circulating levels of E2 are high. Therefore, neuroendocrine interactions, in part, explain sex differences in behaviors motivated by drug reward. Here, we review sex differences in the physiology and function of the mesolimbic reward system in order to explore the notion that sex differences in response to drugs of abuse, specifically cocaine and opiates, are the result of molecular neuroadaptations that differentially develop depending upon the hormonal state of the animal. We also reconsider the notion that ovarian hormones, specifically estrogen/estradiol, sensitize target neurons thereby increasing responsivity when under the influence of either cocaine or opiates or in response to exposure to drug-associated cues. These adaptations may ultimately serve to guide the motivational behaviors that underlie the factors that cause women to be more vulnerable to cocaine and opiate addiction than men.

Keywords: estrogen, dopamine, female, withdrawal, mesolimbic reward system

INTRODUCTION

Drug addiction or substance use disorder is a chronic, relapsing, neuropsychiatric illness characterized by a loss of control over drug seeking and intake, persistent drug craving, and high motivation to take the drug (Reid et al., 2012). Here we provide an updated review, of the literature in which we discuss sex differences in the development of cocaine and opiate addiction, with an emphasis on the influence of estradiol (E2) on signaling within the mesolimbic reward circuit. We provide an overview of the mechanisms of the mesolimbic reward circuit and have described in detail how E2 influences it at the circuit level and also at the level of dopaminergic signaling. Furthermore, we have included discussions of molecular mechanisms underlying the sex differences in the behavioral responses to cocaine and opiates and have demonstrated the
role of E2 in the modulation of these mechanisms. Taken together, this review demonstrates the link between sex differences in cocaine and opiate addiction and the role of E2 as a major driver of these sex differences. Many excellent reviews have been published on sex differences in addiction and drug abuse. Some of the most recent of these have detailed sex differences in the balance between dorsal and ventral striatal circuits (Becker, 2016); quantitative, population, and mechanistic sex differences in addiction (Becker and Koob, 2016); basic biological differences between males and females that influence addictive behaviors (Becker et al., 2017); sex differences in biology, epidemiology, and treatment of substance use disorder (McHugh et al., 2018), and, most recently, a comprehensive review which highlights sex differences in the neural mechanisms and developmental events influencing addiction vulnerability (Becker and Chartoff, 2019).

**Sex Differences in Addiction to Cocaine**

Cocaine use disorder is a serious public health concern. In the United States, approximately 2.2 million people report regular use of cocaine and 1 million individuals met criteria for cocaine use disorder in the past year (Substance Abuse and Mental Health Services Administration, 2018). Although, overall, more men use and are addicted to cocaine than women, women exhibit a more rapid progression from initial cocaine use to dependence than men (Kosten et al., 1985; Brady and Randall, 1999). Women also report experiencing enhanced positive subjective effects (feelings of euphoria) of cocaine than men. The enhancement of positive subjective effects is speculated to be the reason women more rapidly progress through the stages of addiction than men (reviewed in Becker and Hu, 2008). During periods of abstinence, women report experiencing higher levels of cocaine craving and relapse rates than men. Lastly, during bouts of relapse women take larger amounts of cocaine than men (Kosten et al., 1985; Brady and Randall, 1999; Robbins et al., 1999; Chen and Kandel, 2002; Gallop et al., 2007; Ignjatova and Raleigh, 2009). Collectively, these data indicate that women may be more severely affected by cocaine use than men.

**Sex Differences in Addiction to Opiates**

Opioid use disorder (OUD) has reached epidemic proportions, claiming ~115 lives daily to opioid overdoses in the US alone (Substance Abuse and Mental Health Services Administration, 2015; The, 2017; Volkow et al., 2019). Opioids acutely attenuate perceptions of pain and induce euphoria and relaxation in users. Despite the acute benefits, long-term opioid use can lead to the development of OUD (The, 2017; Volkow et al., 2019). Individual differences in addiction liability exist, and behavioral traits like impulsivity and risk-taking behavior often heighten the risk for users to transition from recreational drug use to drug dependence (Kreek et al., 2005; Belin et al., 2008). The influence of sex/gender in the physiological/psychological risks for developing OUD has also been reported (Fillingim et al., 2009; Green et al., 2009; Back et al., 2010). Overall, more men than women report lifetime and past-year use of all opioid drugs. However, women are more likely to report the non-medical use of prescription opioids as their primary drug of abuse (Center for Behavioral Health Statistics and Quality, 2015). This is likely because women are more likely to suffer from chronic pain conditions (Darnall et al., 2012), be prescribed prescription pain relievers, and use them for longer time periods than men (Berkley, 1997; Gureje et al., 1998; Fillingim et al., 2009; Mogil, 2012; Centers for Disease Control and Prevention, 2013; Substance Abuse and Mental Health Services Administration, 2014; Serdarevic et al., 2017). In addition, compared to men, women (a) are more likely to use opioids for non-medical conditions (Green et al., 2009; Hensing et al., 2016; Marsh et al., 2018); (b) transition more rapidly from casual to non-medical use of prescription opioids to opioid dependence; (c) experience higher levels of craving and relapse during abstinence; (d) consume larger amounts of drug during relapse; and (e) are less likely to seek treatment for their opioid addiction (Kosten et al., 1985; Brady and Randall, 1999; Ignjatova and Raleigh, 2009; Bobzean et al., 2014a). In addition, during periods of abstinence, women report higher numbers of distressing physical/affective withdrawal symptoms compared to men (Soldin et al., 2011; Fox et al., 2013; Fernandez-Montalvo et al., 2017; Dunn et al., 2018). While, men are more likely to die from opioid overdose than women, overdoses related to opioids have greatly increased in women compared to men: from 1999 to 2017 opioid overdose-related deaths increased in women by 471% as compared to 218% among men (Paulozzi et al., 2011; Serdarevic et al., 2017; VanHouten et al., 2019). Therefore, it is not surprising that several studies identify women as one of the most vulnerable subpopulations for non-medical prescription opioid use and abuse (Fillingim et al., 2009; Green et al., 2009; Back et al., 2010).

**THE ROLE OF THE MESOLIMBIC REWARD SYSTEM IN ADDICTION**

The mesolimbic reward system is necessary for organisms to engage in reinforcing behaviors and to motivate actions that produce rewarding feelings of pleasure (Gardner, 2011). Midbrain dopamine (DA) neurons that arise in the ventral tegmental area (VTA) and substantia nigra project to forebrain regions (striatum, prefrontal cortex, hippocampus, and amygdala) that regulate the motivational and cognitive processes necessary for organisms to engage in behaviors that produce rewarding feelings of pleasure (Wise, 2004) (Figure 1). These pathways modulate information flow through the limbic system to regulate and/or promote behaviors related to survival and perpetuation of the species (i.e., feeding, drinking, mating, maternal and paternal behaviors, and social interaction) (White and Milner, 1992; Gardner, 2011). Chronic drug use produces a persistent enhanced activation of these systems which results in long-term structural and functional changes (Nestler, 2016). Drug-induced enhanced activation of these systems, in turn, alters the motivational and cognitive processes arising from these systems in such a way that the drive to obtain and use drugs supersedes other drives (Anselme, 2009; Goldstein and Volkow, 2011; Buchta and Riegel, 2015; Zorrilla and Koob, 2019).

**VTA in Drug Addiction**

The VTA contains two major classes of DA projection systems: the mesolimbic system which regulates rewarding motivational processes including feeding, drinking, sex, drug...
consumption and continued drug use, and the mesocortical DA system which regulates cognitive/executive functions such as working memory, drug-cue associations, cue-induced reinstatement of drug use (Figure 1) (Le Moal and Simon, 1991; Bjorklund and Dunnett, 2007).

**Striatal Complex in Drug Addiction**

The striatal complex, generally speaking, gathers inputs from the neocortex, and then sends projections to other nuclei of the basal ganglia which ultimately reach cortical areas implicated in motor planning and execution. The striatum is a structure that is highly conserved across species and critically important for a broad range of cognitive, sensorimotor, and limbic-related functions. The striatal complex is anatomically divided into the ventral striatum (nucleus accumbens) and dorsal striatum (caudate putamen) (Voorn et al., 2004; Yin et al., 2004).

### Dorsal Striatum

The dorsal striatum (DS) can be subdivided into dorsomedial striatum (DMS), which is vital for goal-directed learning, and the dorsolateral striatum (DLS) implicated in stimulus-response learning (Yin et al., 2005, 2006). Compulsive responding to drug-associated cues is established when the DS is engaged by the intrastriatal loops between the NAc and DS. Thereafter, exposure to drug-associated cues induces activation of the DS without the presence of the drug. Such activation of DS neurons may induce craving for the drug and has been proposed to be the initiator of drug seeking and relapse (Koob and Volkow, 2016).

### Nucleus Accumbens (a.k.a. Ventral Striatum) in Addiction

The NAc is a heterogeneous structure and is subdivided into shell and core components which are chemoarchitecturally and functionally distinct (Zahm and Brog, 1992; Groenewegen et al., 1999; Di Chiara, 2002). The central area of the NAc, called the NAc core, is distinct and is surrounded medially, ventrally, and laterally by the NAc shell. The differences between the NAc core and NAc shell are defined by a number of histochemical, electrophysiological, connectional, and cellular criteria (Zahm and Brog, 1992; Groenewegen et al., 1999; Di Chiara, 2002). Anatomically, the NAc core/shell subdivisions can be differentiated in terms of the input they receive from prefrontal cortical regions: The NAc core receives the majority of its prefrontal input from the prelimbic region of the cortex and lateral orbitofrontal cortex; the NAc shell receives its cortical input from infralimbic cortex and medial lateral orbitofrontal cortex (Berendse et al., 1992; Wright and Groenewegen, 1996). These accumbal subregions are also dissociable in terms of their pallidal/nigral projection outputs: The core projects predominantly to the substantia nigra while the shell targets the pallidum and the VTA (Heimer et al., 1991; Zahm and Brog, 1992; Zahm and Heimer, 1993; Ikemoto, 2007). There is some evidence to suggest communication between MSNs within the ventral striatum. Within the NAc, the core and shell share important intra-structural connections which may be important for the combination of diverse limbic inputs to be later integrated for output to other structures (van Dongen et al., 2005, 2008).

The NAc core is critically involved in the development and expression of addiction-related behaviors (Koob and Volkow, 2010) and is recruited in Pavlovian conditioning (Koos and Tepper, 1999; Lof et al., 2007; Sunday and Rebec, 2014). For example, typically, NAc core interacts with brain regions associated with motor circuitry, thus coordinating behavioral output, while the shell interacts with limbic and autonomic brain regions, indicating significant regulation of reward, emotional, and visceral responses to stimuli (Heimer and Alheid, 1991; Zahm and Brog, 1992; Everitt et al., 1999). As
such, the shell is suspected to mediate the reinforcing properties of novelty, feeding behavior, rewarding substances and stimuli which induce drug relapse, while the core seems to play a role in spatial learning, conditioned responses, responses to motivational stimuli, and impulsive choices. Together, the NAc core and shell control the enactment and reinforcement of conditioned behaviors through interaction with reward circuitry (Meredith et al., 2008). In this way, it is generally accepted that the NAc shell is more involved in shorter-term aspects of addiction, for instance reward; whereas, the NAc core plays a role in longer lasting reward-directed behaviors (Ito et al., 2004; Meredith et al., 2008).

**Prefrontal Cortex in Drug Addiction**

The VTA sends dopaminergic (DA) projections to the medial prefrontal cortex (mPFC). These DA projections activate the glutamatergic systems of the prefrontal cortex. Glutamatergic projections from the prefrontal cortex (PFC) directly activate mesocortical DA neurons in the VTA and exert excitatory control over DA cell firing and release in the PFC (Geisler and Wise, 2008). The PFC also sends glutamatergic projections to the dorsal and ventral striatum which modulates the control of pallidal/nigral pathways. In this way the PFC is in a good position to regulate salience and conditioned behavior in response to salient stimuli (Koob and Volkow, 2016). Protracted abstinence from drugs of abuse leads to over activation of the glutamatergic systems that induce strong craving-like responses via glutamatergic activation of the NAc (McFarland and Kalivas, 2001; De Witte et al., 2005), thus indicative of this circuit’s importance in cravings associated with drugs of abuse. Drug-induced reinstatement also involves glutamatergic projections to the NAc that modulate DA release within the NAc (Koob and Volkow, 2016).

**Hippocampus in Addiction**

The hippocampus has been implicated in the formation of drug-context memories, drug-cue associations, and reconsolidation of drug memories. In addition, the hippocampus has been implicated in reinstatement of drug-taking behavior leading to relapse via cue and contextual triggers (Kutlu and Gould, 2016).

**Amygdala in Addiction**

The basolateral amygdala (BLA) plays a critical role in the response to natural reward and drug-associated cues. Anatomically, the BLA receives DA inputs from the VTA and provides outputs to neurons in the NAc (Floresco et al., 1998, 2001; Bissière et al., 2003; Ford et al., 2006). Because the BLA serves as an interface between VTA DAergic inputs and outputs to the PFC and NAc, it is well positioned to subserve associative memory functions. Through the convergence of DAergic inputs with sensory-associative information, BLA neurons encode emotionally salient memories (Grace and Rosenkranz, 2002; Rosenkranz and Grace, 2002). The BLA is implicated in the associative properties of opiate-related learning (Fuchs and See, 2002). Increases in activity in adjacent central nucleus of the amygdala (CeA) are associated with the anxiety-like effects of acute withdrawal and the increased drug intake associated with dependence (Koob and Le Moal, 2008).

**SEX DIFFERENCES ON MESOLIMBIC REWARD SYSTEM FUNCTION**

In this section, we discuss sex differences that have been identified and described within the mesolimbic reward system. Sexual dimorphisms have been established in both the underlying organization of the midbrain DA circuitry, as well as the influence of estradiol on DA activity (Figure 1).

**Sex Differences in the VTA**

Sex and levels of ovarian hormones influence DA cells in the VTA (Morissette et al., 2008; Gillies and McArthur, 2010; Johnson et al., 2010). Female rodents have a significantly greater proportion of DA neurons in the VTA compared to their male counterparts (Kritzner and Creutz, 2008). In addition, sex differences in the shape and volume of the VTA as well as in the distribution and size of DA cell populations have been identified (McArthur et al., 2007).

Although baseline firing activity of DA cells in the VTA of male and female rodents is reported to be equivalent (Locklear et al., 2017; Rincon-Cortes and Grace, 2017), the activity of VTA-DA neurons appears to be sensitive to circulating levels of estradiol (E2). For example, basal firing rates of DA neurons of the VTA vary during the different phases of the rodent estrous cycle: DA firing rates are highest in estrus, lowest in proestrus, and intermediate in diestrus (Zhang et al., 2008). Moreover, E2 replacement to ovariectomized (OVX) rats influences firing rate, spontaneous activity, DA release, DA transporter activity, and overall responsiveness of striatal neurons to DA (Zhang et al., 2008; Calipari et al., 2017). In addition, DA receptor auto-inhibition is also E2 sensitive, demonstrating greater inhibition with increasing levels of E2 over the estrous cycle and increased inhibition in OVX-E2 treated mice (Vandegrift et al., 2017). Overall, the ability of E2 to influence activity of VTA-DA neurons strongly suggests the involvement of locally expressed estrogen receptors (Shughrue et al., 1997; Creutz and Kritzner, 2002; Milner et al., 2010).

**Sex Differences in the Striatal Complex**

The GABAergic medium spiny neuron (MSN) is the predominant striatal neuron type (~95%) (Gerfen and Surmeier, 2011). GABAergic MSNs of the DS are capable of influencing both motor and cognitive behaviors via their projections to other brain regions (Yager et al., 2015). GABAergic MSNs work intricately to integrate inputs from a number of different brain areas to determine the final output of the striatum. For example, GABAergic MSNs of the NAc make inhibitory connections with cells in the ventral pallidum and VTA, and receive excitatory input from the prefrontal cortex, ventral subiculum of the hippocampus and basolateral nucleus of the amygdala (Sesack et al., 2003; Kauer and Malenka, 2007). MSNs also receive other inputs (predominantly excitatory) from multiple brain regions
implicated in mediating striatal function (Russo and Nestler, 2013; Scofield et al., 2016).

Robust sex differences and hormone sensitivity in the NAc core are well documented (Becker, 1999; Becker and Hu, 2008; Yoest et al., 2014). Reports of sex differences/hormone sensitivity in NAc shell are less robust and/or more variable compared to core and likely depend upon interactions with other environmental influences (Forlano and Woolley, 2010; Brancato et al., 2017). The sex differences in the NAc core appear to be mediated primarily via influences on excitatory synaptic and electrophysiological properties of NAc neurons and striatal terminals (Mermelstein et al., 1996; Wissman et al., 2011; Dorris et al., 2015). In addition, sexual dimorphisms in synaptic properties and dendritic spine density of GABAergic MSNs in the NAc core have also been identified. In females, GABAergic MSNs of NAc core have anatomically larger spines and higher dendritic spine density than in males (Forlano and Woolley, 2010) and the frequency of mEPSCs in the core is higher in females than males (Wissman et al., 2011). In both the core and shell there is no evidence for sex differences in the number of DA neurons (Forlano and Woolley, 2010; Wissman et al., 2012). Other neuroanatomical attributes such as MSN soma size, cellular density and gross region volume have not been found to be sexually dimorphic (Meitzen et al., 2011; Wong et al., 2016). Electrophysiological properties of GABAergic MSNs in the core change across the estrous cycle (Proano et al., 2018). For example, during diestrus, the excitatory synaptic input onto these MSNs decreases in magnitude, while intrinsic excitability increases. In other words, mESPC frequency and amplitude are decreased during diestrus compared to other estrous cycle phases, while properties such as action potential rheobase, threshold, input resistance, and resting membrane potential change to increase cellular excitability (Proano et al., 2018). During proestrus and estrus excitatory synaptic input increases and intrinsic excitability decreases. Frequency and amplitude of mEPSCs are also increased compared to diestrus phase (Proano et al., 2018). These findings demonstrate the likelihood that higher and lower levels of E2 differentially regulate the electrophysiological properties of GABAergic MSNs of the NAc core. Based on these data, it can be inferred that lower levels of E2 during diestrus may permit tonic activation of GABAergic MSNs while higher levels of E2 during proestrus and estrus induces GABA release.

The major target of the VTA-DA projections is striatal GABAergic MSNs (Figure 1). Within the NAc, subpopulations of MSNs are distinguished based on expression of DA receptor subtype and connectivity to other structures (Gerfen et al., 1990). These include, D1 receptors which have an excitatory influence on movement and reward project directly to the substantia nigra reticulata and D2 receptors which most often have inhibitory effects and project to the external segment of the globus pallidus (Deng et al., 2006; Garcia-Carmona et al., 2015; Volkow and Morales, 2015). These neurons can be further defined by their transcriptional profiles: D1substance P and dynorphin and D2 enkephalin (Gerfen et al., 1990; Lobo and Kennedy, 2006; Heiman et al., 2008). It has been suggested that 5–15% of dorsal striatum MSNs can express both D1 and D2 receptors (Lester et al., 1993; Bertran-Gonzalez et al., 2008; Perreault et al., 2011). D1-MSNs are equally distributed throughout the core and shell (Gangarossa et al., 2013). D2-MSNs are homogeneously distributed in the core but in the shell, they are more expressed in the medial and ventral shell (Gangarossa et al., 2013).

The striatum of male rats contains about 10% more D1 DA receptors than that of intact female or OVX rats. Generally speaking, there are no sex differences in the number or binding characteristics of striatal D2 DA receptors (Hruska and Silbergeld, 1980; Levesque and Di Paolo, 1988), however, one experiment reported female rats had fewer D2 receptors than males (Miller, 1983). Interestingly, E2 rapidly downregulates D2 DA receptor binding in the striatum of females (Bazzett and Becker, 1994).

Sex differences and E2 sensitivity of striatal DA kinetics have been well documented (Yoest et al., 2018). For example, administration of E2 to OVX rats increases DA release, turnover, and DA uptake (Becker and Ramirez, 1981a; Becker and Beer, 1986; Di Paolo, 1994). In addition, E2 acutely increases DA receptor density and DA binding (Di Paolo et al., 1985; Levesque and Di Paolo, 1989; Di Paolo, 1994; Shieh and Yang, 2008). Evidence from studies using intact rodents add to the above studies and clearly demonstrate sex differences in baseline DA activity and stimulated DA activity in the striatum (Becker, 1999; Becker and Hu, 2008; Becker et al., 2012). More specifically, female rats exhibit greater basal concentrations of DA and stimulated DA concentrations in the striatum compared to those of males (Castner et al., 1993; Walker et al., 2000). The ratio of levels of striatal DOPAC/DA (a measure of neurotransmitter turnover) are highest during the proestrus stage of the estrous cycle as compared to the other stages of the cycle, suggesting a greater magnitude of DA turnover when circulating levels of E2 are high (Xiao and Becker, 1994).

SEX DIFFERENCES IN THE BEHAVIORAL RESPONSE TO DRUGS OF ABUSE

Like humans, female rodents escalate administration of cocaine and opioids more rapidly than males (Becker and Chartoff, 2019). Females rodents also demonstrate higher motivation to consume cocaine and opioids than their male counterparts (Becker and Chartoff, 2019). In addition, females consume larger quantities of drug (under some but not all conditions) and experience increased rewarding effects of cocaine and morphine compared to their male counterparts (reviewed in Becker and Koob, 2016). Post abstinence, female rodents consume greater amounts of the drug and demonstrate greater dysregulation of drug intake when given free access to drugs than males (Lynch and Taylor, 2004, 2005; Fuchs et al., 2005; Kosten and Zhang, 2008). Females also demonstrate increased responsivity toward drug taking under stress than males indicating a higher intensity of negative physical and psychological withdrawal symptoms and therefore, higher relapse probability (Fox and Sinha, 2009). Lastly, female rodents more readily reinstate drug use after a
period of abstinence in the absence of any reinforcing cues when compared to males (Anker and Carroll, 2010; Buffalari et al., 2012). Taken all together, these data demonstrate sex differences in preclinical rodent models of drug administration/reward and recapitulate and extend findings from the clinical literature. Specifically, female rodents are decisively more vulnerable to developing addiction-like behaviors after exposure to drugs of abuse than males. Although animal models of drug addiction do not emulate exactly what happens in humans, the assessment of the behaviors that occur after ingestion of drugs of abuse have demonstrated good face validity in that they allow for the objective understanding of specific signs and symptoms of the addiction process. They also allow quantification of psychological constructs like drug reward and affective states. Ultimately, much of the extant scientific literature involved in the understanding of underlying neurobiology and pathophysiology of drug addiction comes from the use of animal models of drug addiction. With regard to this review, almost all evidence-based inferences to demonstrate the interaction between estradiol and mesolimbic reward circuitry toward the vulnerability of women to drug addiction have been derived from the preclinical rodent literature. This further elaborates the validity of the use of these rodent models toward understanding the basis of sex differences in drug addiction.

**The Menstrual and Estrous Cycle Influence Addictive Behaviors**

In females, the phase of the menstrual/estrous cycle and the release of reproductive hormones associated with each phase, influences synaptic transmission, sex-specific motivated behaviors, as well as motivation related to drug-taking and addiction-related behaviors (Figure 2). Therefore, it is essential that the hormonal conditions of women be taken into consideration when discussing sex differences in addiction.

The human menstrual cycle has a 28-day duration and consists of follicular, periovulatory, and luteal phases. During the follicular phase (10–12 days), estradiol (E2) is secreted from the ovary as the follicle develops and circulating concentrations of E2 increase daily. The next phase is the peri-ovulatory phase (2–4 days) during which a surge of E2 prompts the release of luteinizing hormone from the pituitary that induces ovulation. The next phase is the luteal phase (10–12 days) which is characterized by the release of relatively high concentrations of both E2 and progesterone from the remains of the ruptured follicle (corpus luteum). Menstruation occurs at the end of the luteal phase after the fall in progesterone and E2 secretion once the corpus luteum has regressed (unless pregnancy occurs). Hormone levels are at their lowest points during menstruation indicating the beginning of the next follicular phase (Becker et al., 2005). Rats and mice have a 4–5 days estrous cycle comprised of phases that function similarly to the phases in the human menstrual cycle. The rat/mouse follicular phase (2–3 days) is called diestrus. The periovulatory phase of the rat and mouse is called proestrus and occurs during the day of E2 and progesterone surges. The estrus phase of the rat/mouse cycle occurs on the day following the E2 and progesterone surges; this is when the female rodent ovulates and is sexually behaviorally receptive (Becker et al., 2005).

**Cocaine**

It is well established that compared to males female rats demonstrate more robust operant behavior during acquisition of cocaine self-administration, escalation of drug intake, and reinstatement of extinguished drug-taking behavior (Lynch and Carroll, 1999, 2000; Roth and Carroll, 2004). Moreover, female rats acquire cocaine self-administration more quickly and at lower doses than males (Lynch and Carroll, 1999; Davis et al., 2008).

Estrous cycle phase has been shown to influence an animal’s motivation to self-administer cocaine (Roberts et al., 1989); cocaine-self administration is highest during proestrus and estrus and lowest during diestrus (Feltenstein et al., 2011). In other words, female rats consume greater amounts of cocaine when circulating levels of E2 are high and cocaine consumption is reduced at times when E2 levels are lower. The notion that different levels of circulating ovarian hormones are important for differences in the reinforcing properties of drugs is further supported by self-administration paradigms using OVX-hormone-treated rodents. Such experiments have consistently demonstrated a role for E2 in enhancing the responsivity to cocaine. More specifically, ovariectomy alone decreases the rate of acquisition of cocaine self-administration and reinstatement of previously extinguished cocaine-seeking behavior. E2 administration to OVX animals restores acquisition of cocaine self-administration to levels comparable with those of intact female rodents (Lynch et al., 2001; Hu et al., 2004; Larson et al., 2005; Frye, 2007). Furthermore, this effect was specific for female rodents since there was no effect of E2 replacement on cocaine self-administration behaviors of male rodents (Jackson et al., 2006).

Continued drug use, drug-seeking and relapse to former patterns of drug use during abstinence are heavily dependent on learning associations between the drug and environmental cues and/or contexts as well as the individual’s physical and emotional reactivity to these stimuli (O’Brien et al., 1990; Enmark et al., 1997). Susceptibility of females to cocaine-associated cues and contexts is an important underlying factor in the sex-differences seen in cocaine addiction (Robbins et al., 1999). The conditioned place preference paradigm (CPP) is used to determine the conditioned rewarding effects of drugs in rodents because the contextual (environmental) cues used within the paradigm acquire secondary appetitive properties when paired with a rewarding stimulus (i.e., drug of abuse) (Bardo and Bevins, 2000; Tzschentke, 2007). Additionally, the cues/context itself acquires rewarding properties that are directly associated with the subjective rewarding effects of the drug. Sex differences in the rewarding properties of cocaine have been well illustrated using this paradigm by our group and others. Specifically, female rats demonstrate acquisition of conditioned place preference to lower doses of cocaine compared to males (Russo et al., 2003b; Zakharova et al., 2009). This indicates that at lower doses females experience an increase in the magnitude of the rewarding effects of cocaine when compared to males (Russo et al., 2003b;...
Kokane and Perrotti

Sex Differences in Cocaine and Opiate Addiction

FIGURE 2 | The human menstrual cycle and rat estrous cycle. The human menstrual cycle (left) occurs over 28 days and is comprised of fluctuating levels of E2 (E2; top) and progesterone (P4; bottom). Levels of E2 rise to a peak during the peri-ovulatory phase. E2 levels then drop, rise, and plateau between during the mid-luteal phase (approximately Days 14–28). Progesterone (P4) levels begin to at the end of the ovulation (Days 0–14) and reach their peak during the mid-luteal phase of the cycle (approximately Day 7). The rat estrous cycle (right) is similar to the human menstrual cycle but occurs over a 4/5-day period. Four phases; metestrus, diestrus, proestrus, and estrus comprise the rat estrous cycle. Estrogen levels (top) peak toward the end of diestrus and beginning of proestrus. Progesterone levels (bottom) reach a peak during mid-proestrus.

Zakharova et al., 2009). However, at higher doses, cocaine place preference is similar between males and females. This suggests that female sensitivity to cocaine’s effects is dose dependent and maybe acutely enhanced at lower doses. Circulating levels of E2 influence the magnitude of CPP, however, these effects vary according to the dose and length and time course of hormone treatment. We and others have reported that OVX female rats demonstrate lower CPP scores compared to intact females (Russo et al., 2003a; Kokane et al., 2019). In a series of experiments in which chronic continual administration of E2 was given throughout the duration of the CPP paradigm, E2 treatment alone did not influence CPP when compared to untreated animals (Russo et al., 2003a). Recent studies from our laboratory, demonstrate that low dose E2 administration to OVX female rats during the conditioning phase of CPP enhances expression of cocaine place preference (Kokane et al., 2019). Conversely, a single injection of E2 prior to the test phase of cocaine CPP, blunted the expression of cocaine place preference in OVX rats (Bobzean et al., 2014a). This finding indicates that elevations in E2 after drug-associations have taken place, my actually serve to inhibit the conditioned response or decrease the salience of the stimulus. Taken together these data elaborate the influence of E2 on the rewarding and reinforcing properties of cocaine. It is also evident from the above studies that the timing of the elevations in E2 levels is important toward these effects.

Morphine

Overall, female rodents acquire both oral and IV self-administration of opioids faster than males, at lower doses, and under a wider variety of environmental housing factors (Alexander et al., 1978; Lynch and Carroll, 1999; Cicero et al., 2003). Moreover, females consume greater amounts of opioids and will work harder for a dose of an opioid drug than males (Cicero et al., 2003). In tests of CPP, female mice
Sex differences in behavioral effects of cocaine are largely the result of underlying neurobiological changes brought about by the interactions between cocaine and ovarian hormones within reward-related circuitry. Although specific neurobiological mechanisms remain to be fully elucidated, there is much evidence implicating the combined effect of cocaine and E2 on mesolimbic reward circuitry. The repeated administration of cocaine causes adaptations in synaptic plasticity and dendritic arborization within areas of the mesolimbic reward pathway. The increased neurotransmission (GABAergic, dopaminergic, and glutamatergic) activates downstream molecular mechanisms within these areas. Estradiol has been shown to modulate the activity of these molecular mechanisms. In this section, we discuss the influence of E2 on the molecular mechanisms which underlie the persistent effects of cocaine and morphine on the structural and functional changes in the mesolimbic reward system.

Cocaine

Cocaine exerts its psychomotor stimulant effects by increasing extracellular DA levels by binding to the dopamine transporter (DAT) in the striatum; a membrane protein located on nerve terminals responsible for the reuptake of DA from the synaptic cleft (Mortensen and Amara, 2003; Zhu and Reith, 2008). Through this inhibition of DA reuptake, cocaine increases synaptic DA levels thereby potentiating activation at postsynaptic DA receptors. Cocaine produces a buildup of DA wherever the brain has DA transporters. However, the psychoactive and addictive effects of cocaine are generated by the drug’s ability to produce a buildup of DA in mesolimbic reward structures (Koob et al., 1998; Hyman and Malenka, 2001; Nestler, 2001; Kalivas and McFarland, 2003).

Activation of G-protein-coupled D1 receptors initiates a cellular signaling cascade that enhances phosphorylation of the transcription factor cAMP response element binding protein (CREB) and expression of immediate-early genes (Nestler, 2002; Walters et al., 2003). Generally speaking, the positive rewarding effects of cocaine are mediated via D1-MSNs (Hikida et al., 2010; Lobo et al., 2010; Lobo and Nestler, 2011; Bock et al., 2013; Chandra et al., 2013; Lenz and Lobo, 2013) and many cocaine-induced molecular adaptations occur within these D1 MSNs (Lobo and Nestler, 2011; Grueter et al., 2013; Lobo et al., 2013). The increases in cAMP in response to D1 receptor stimulation initiate activation of downstream protein kinases, including protein kinase A (PKA) and extracellular signal-regulated kinase (ERK). These kinases, along with many other downstream effects, can phosphorylate the transcription factor CREB (Kano et al., 1995). CREB activation in the NAc is essential as a regulator of cocaine reward and for cocaine-dependent alterations in gene expression (McClung and Nestler, 2003; Lemberger et al., 2008; Renthal et al., 2009). Post synaptic D2 receptors either inhibit or have no effect on adenylyl cyclase activity; presynaptic D2 receptors function as auto-receptors (Clark and White, 1987; Meador-Woodruff et al., 1991; Surmeier et al., 2007). Generally speaking, D1 receptors play a role in the primary rewarding properties of cocaine, while D2 receptors play a role in drug-seeking mechanisms (Self et al., 1996; Lobo and Nestler, 2011). The repeated administration of cocaine causes adaptations in such DA receptor stimulated signaling pathways which manifest into the behaviors characteristic of cocaine addiction (Anderson and Pierce, 2005; McGinty et al., 2008; Thomas et al., 2008).

Overview of Signaling Mechanisms of Cocaine Addiction

Molecular mechanisms associated with cocaine reward, reinstatement, craving and dependence involve extracellular signal regulated kinase (ERK), calcium/calmodulin-dependent kinase II (CaMKII), protein kinase C (PKC), cAMP-dependent protein kinase A (PKA), cGMP-dependent protein kinase G (PKG), phosphatidylinositol 3-kinase (PI3K) and its downstream target mammalian target of Rapamycin (mTOR), cyclin-dependent kinase 5 (Cdk5), transcription factors (cAMP response element binding protein – CREB, nuclear factor-kappa B – NF-kB, delta Fos B – ΔFosB) and brain derived neurotrophic factor (BDNF).

CREB, NF-κB, and ΔFosB are transcription factors regulating the expression of several genes involved in synaptic plasticity, neuroadaptations dendritic arborization and have been implicated in the development of cocaine addiction-related behaviors. CREB gets phosphorylated by PKA, CaMKII and ERK signaling pathway. Increased phosphorylation of CREB in the NAc, blunts the rewarding effects of cocaine thereby driving cocaine self-administration (Carlezon et al., 1998; Barrot et al., 2002; Larson et al., 2011). Through empirical evidence, it has been proposed that increased activity of CREB leads to increased excitability of NAC MSNs via increased expression and synaptic transmission of NMDARs. This may in turn induce a negative feedback loop that blunts rewarding effects of cocaine and eventually drives escalation (Dong et al., 2006). Phosphorylation of CREB also drives formation of new dendritic spines by increasing the expression of NMDARs but not AMPARs leading to the formation of “silent synapses” (Murphy and Segal, 1997; Segal and Murphy, 1998). Studies have indicated formation of “silent synapses” to be critical to the enhancement of cocaine.
Gene expression directly, by binding to consensus target DNA upon ligand binding and dimerization (Nilsson et al., 2001). As factors which reside in the cytosol and translocate to the nucleus classical estrogen receptors” are ligand-activated transcription genomic and non-genomic actions. The so-called “genomic or It is well established that estrogens produce their effects by

Intracellular Signaling

Estrogen Receptors Influence Cocaine-Induced

sex differences in baseline and cocaine-induced activation of cAMP and PKA pathways in the NAc have been documented. Overall, female rats exhibit higher levels of total PKA protein and phosphorylated DARPP-32 in the NAc compared to males, regardless of drug-treatment condition (drug naïve, saline-treatment, or cocaine-treatment) (Lynch et al., 2007; Nazarian et al., 2009). Moreover, males and females have different basal and cocaine-induced levels of pERK, A-FosB, and pCREB in the NAc (Nygard et al., 2013). It is possible that this may be due to the differences in DA receptor expression and binding (Yoest et al., 2018). Studies have also shown E2 regulation of cAMP and PKA pathways. For example, the estrous cycle seems to affect the activity of a variety of intracellular signaling cascades in the NAc of female rats regardless of cocaine-treatment (Weiner et al., 2009). Ovariectomized females have been used in attempts to identify a role of E2 on these intracellular signaling cascades. The results of one study show that OVX E2 treated females demonstrate E2-induced initiation of PKA cascades and CREB protein phosphorylation via activation of G-protein dependent cell signaling cascades (Hammes and Levin, 2007). The downstream effects of these results likely contribute to the structural sexual dimorphisms seen in dendritic morphology and spine density (Forlano and Woolley, 2010; Wissman et al., 2011, 2012).

Estrogen Receptors Influence Cocaine-Induced Intracellular Signaling

It is well established that estrogens produce their effects by genomic and non-genomic actions. The so-called “genomic or classical estrogen receptors” are ligand-activated transcription factors which reside in the cytosol and translocate to the nucleus upon ligand binding and dimerization (Nilsson et al., 2001). As with other steroid hormone receptors, ERs can either modulate gene expression directly, by binding to consensus target DNA sequence, or indirectly, by interacting with other transcription factors to activate or repress gene activation. Estrogen also has acute, rapid (non-genomic) effects, which are initiated via binding at plasma associated membrane estrogen receptors (mER) (Boulware et al., 2005; Mermelstein and Micevych, 2008; Micevych and Mermelstein, 2008). Signaling at mERs activates G-protein dependent cell signaling cascades (Hammes and Levin, 2007), including PKA and MAPK (Dhandapani and Brann, 2002; Bjornstrom and Sjoberg, 2005; Ronnkleiv et al., 2007; Vasudevan and Pfaff, 2007). These signaling cascades are similar to those initiated by DA at D1 receptors. In fact, evidence for the role for mERs in mediating the rapid effects of E2 stems from its effects on CREB phosphorylation (pCREB). ERα and ERβ antagonists mimic the effects of E2 while the mER antagonist ICI 182,780 blocks the rapid effects of E2 on pCREB. In this way, E2 activates both mER and D1 receptor G-protein-dependent cell signaling cascades including activation of the MAPK pathway, and phosphorylation of CREB (Hammes and Levin, 2007).

Adult female rats predominantly express membrane-bound ERs (GPER1, membrane associated ERα and ERβ) in MSNs of the DS and NAc, but express few or no nuclear ERs (Mermelstein et al., 1996; Kuppers et al., 2008; Schultz et al., 2009; Grove-Strawser et al., 2010; Almey et al., 2012, 2015). Membrane ERs are expressed on axon terminals, somas, and dendritic spines (Almey et al., 2012, 2015, 2016). Functionally, the activation of MSN membrane ERs have been shown to increase sensitivity to drugs of abuse in females (Tonni Eisinger et al., 2018) and change dendritic spine morphology and density in the NAc (Peterson et al., 2015). Previous work has established that application of E2 rapidly increases DA (Becker, 1998; Pasqualini et al., 1996) and decreases GABA production (Hu et al., 2006) in the NAc and DS which suggests that E2 may indirectly influence DA signaling by first releasing inhibition of GABAergic signaling, and perhaps also directly upon DA-producing regions (such as the VTA). In striatal MSNs, E2, acting through membrane-associated ER alpha and beta receptors coupled to mGluRs modulates phosphorylation of the transcription factor CREB (Mermelstein et al., 1996; Grove-Strawser et al., 2010).

similar to the DS, E2 also rapidly modulates glutamate signaling in NAc core and these effects are sex-specific and bidirectional (Krentzel et al., 2019). The mechanism whereby E2 enhances drug-induced plasticity is via interactions with mGluRs. Specifically, E2 activates mGluR5 signaling in the NAc core, which in turn, leads to alterations in dendritic structure (Grove-Strawser et al., 2010; Martinez et al., 2014; Peterson et al., 2015). These alterations induce neuroadaptations which are long-lasting and cause long-term enhanced activation of the mesolimbic reward pathway. As a result, activation of the reward pathway and DA release in response to “naturally” rewarding stimuli is insufficient. Hence, normal rewarding stimuli become less rewarding and full activation of the reward pathway requires drug consumption.

Estradiol and DA systems interact to modulate striatal function and resultant behavior (Di Paolo et al., 1985; Becker and Beer, 1986; Becker, 1990; Bitar et al., 1991). For example, E2 increases striatal DA release and turnover (Becker and Ramirez, 1981b; Becker et al., 1984; Di Paolo et al., 1985; Becker and
activation of these intracellular signaling cascades influences blocks the rapid effects of E2 on pCREB. Thus, mER mediated (Maharjan et al., 2010), while the mER antagonist ICI 182,780 dual PKA/MEK signaling pathways, leading to pCREB activity involves membrane-initiated E2 signaling, rapid activation of DA efflux (Alyea and Watson, 2009). E2 induction of TH inhibiting PI3 kinase or PKA does not affect E2-mediated decreases L-type calcium channel-mediated CREB activity (Gu et al., 1991; Febo et al., 2003). Therefore, the potentiating effects of E2 on striatal DA activity are, in part, a cause of the sex and hormone-related differences in subjective and physiological responses to cocaine (Becker and Ramirez, 1981b; Becker and Rudick, 1999; Walker et al., 2001; Quinones-Jenab, 2006). The effect of E2 in the female striatum is also mediated by E2 receptors on GABAergic MSNs that enhance DA release via disinhibition of local DAergic terminals (Mermelstein et al., 1996; Mermelstein, 2009; Schultz et al., 2009; Grove-Strawser et al., 2010). Thus effects of E2 on cocaine self-administration and CPP may be due to the ability of E2 to act on mesolimbic DA system to regulate reward and motivation, through the ability of E2 to increase cocaine-stimulated DA release in NAc (Tobiansky et al., 2016) and alter signaling pathways and gene expression in striatum (Le Saux et al., 2006; Grove-Strawser et al., 2010; Peterson et al., 2015, 2016).

Interactions between E2 and cocaine have been demonstrated in that E2 enhances the sensitivity of the DAergic neurons of the VTA to cocaine and increases cocaine-induced DA release in the striatum (Peris et al., 1991; Zhang et al., 2008). A recent study by Calipari et al. (2017) demonstrated that female mice in estrus showed increased cocaine-induced DA release compared to female mice in diestrus or male mice. Indeed, these neurobiological effects resulted from greater firing rate of VTA-DAergic projections and DA release in the NAc of female mice in estrus (Zhang et al., 2008; Calipari et al., 2017). Moreover, these estrous females also displayed increased phosphorylation of dopamine transporter (DAT) protein. Taken together, it can be hypothesized that higher levels of circulating E2 increase DA levels in the NAc which is due to increased inhibition of DAT activity under the influence of cocaine (Calipari et al., 2017).

E2 stimulation of mERs rapidly stimulates MAPK-dependent pCREB, and peripheral administration of E2 initiates MAP kinase and PKA signaling pathways (Mhyre and Dorsa, 2006; Dewing et al., 2007, 2008; Kelly and Ronneklev, 2008) and decreases L-type calcium channel-mediated CREB activity (Gu et al., 1996; Zhou et al., 1996; Boulware and Mermelstein, 2005; Boulware et al., 2005, 2007). Inhibition of either MEK or PKC significantly inhibits E2-mediated DA eflux, while inhibiting PI3 kinase or PKA does not affect E2-mediated DA eflux (Alyea and Watson, 2009). E2 induction of TH involves membrane-initiated E2 signaling, rapid activation of dual PKA/MEK signaling pathways, leading to pCREB activity (Maharjan et al., 2010), while the mER antagonist ICI 182,780 blocks the rapid effects of E2 on pCREB. Thus, mER mediated activation of these intracellular signaling cascades influences the activity of a variety of transcription factors which likely contribute to gene transcription independently of nuclear ER (Mhyre and Dorsa, 2006).

Although extensive research in male animals has attributed several different intracellular signaling cascades to different processes associated with cocaine-addiction, studies of these same intracellular signaling mechanisms in females is almost non-existent. However, based on the above discussion, estradiol and cocaine separately or together, affect all of the aforementioned signaling molecules/transcription factors. Further research demonstrating the influence of estrogen/estradiol on the function/activity of these signaling molecules, transcription factors and BDNF is essentially required.

**Morphine**

Morphine and other opioids exert their rewarding effects through stimulation of mu opiate receptors (MORs) localized at the GABAergic terminals in the VTA (Johnson and North, 1992a; Bonci and Williams, 1997). Opioid activation of MORs disinhibits VTA-GABA neurons, which in turn, increases the release of DA to the NAc (Pontieri et al., 1995; Lecca et al., 2007). The increased release of DA in the NAc induces feelings of euphoria and promotes the development of drug dependence (Wise and Rompre, 1989; Johnson and North, 1992b; Bodnar, 2014).

**Overview of Morphine Addiction Mechanisms**

The MOR is a conventional G-protein coupled receptor in that it is a cell surface protein with seven transmembrane domains consisting of α, β, and γ subunits, and an effector protein. Upon activation by an agonist, the Gα and Gβγ subunits dissociate from one another and subsequently regulate a variety of intracellular effector pathways. In case of the VTA-GABAergic interneurons, morphine activation of MORs, suppresses the release of GABA within the VTA thereby promoting DA release from the DAergic projections arising from the VTA. Acute morphine treatment followed by prolonged abstinence produces burst firing of VTA-DA neurons which is believed to play a role in encoding reward value (Schultz, 2002; Jalabert et al., 2011; Fields and Margolis, 2015). Chronic exposure to morphine results in compensatory changes in the cell that oppose the initial alterations observed after acute exposure. Chronic morphine treatment has been shown to reduce the size of VTA-DA neurons (Russo et al., 2007) and increase basal firing rate (Koo et al., 2012) in male rats thus upregulating levels of DA in VTA-NAc circuits (Beitner-Johnson et al., 1991). Therefore, the rewarding effects of opioids are linked to the drug’s ability to activate the mesolimbic DA pathway (Di Chiara and Imperato, 1988; Pierce and Kumaresan, 2006).

The VTA receives inputs from the tail of the VTA (VTA)(Perrotti et al., 2005)/rostromedial tegmental nucleus (RMTg) (Jhou et al., 2009a) and the NAc (Figure 3). This input is believed to modulate the activity of VTA-DA neurons (Koo et al., 2012; Tan et al., 2012; van Zessen et al., 2012; Taylor et al., 2016). Studies using male rodents show that opioid drugs induce rewarding effects through inhibition of GABAergic interneurons, leading to excitation of VTA-DA neurons (Gysling and Wang, 1983; Johnson and North, 1992b). This VTA-DA excitation is
mediated via GABAergic projections from the tVTA/RMTg. The tVTA/RMTg, caudal to the VTA, is a GABAergic area innervating VTA-DA cells (Bourdy et al., 2014). MORs are densely packed on these tVTA-GABAergic neurons (Jhou et al., 2009b, 2012; Jalabert et al., 2011; Kaufling and Aston-Jones, 2015), and MOR binding decreases their firing rate (Jalabert et al., 2011; Kaufling and Aston-Jones, 2015). Consequently, DA neurons in VTA are disinhibited and freely transmit DA to projection sites in the NAc and other limbic regions which leads to overstimulation of the circuitry mediating addiction-related behaviors. Acute morphine treatment activates VTA-DA neurons via inhibition of GABAergic projections from the tVTA/RMTg (Lecca et al., 2012; de Guglielmo et al., 2015; Kaufling and Aston-Jones, 2015). Naloxone precipitated withdrawal from chronic continual morphine treatment has been shown to increase release of GABA in the tVTA of male rats (Kaufling and Aston-Jones, 2015). Although there is no single brain region responsible, a growing body of evidence supports morphine withdrawal-induced increases in tVTA GABA release in triggering the intracellular events that manifest aspects opiate withdrawal syndrome (Madhavan et al., 2010; Kaufling and Aston-Jones, 2015).

The molecular mechanisms underlying opioid reward and dependence are under the direct control of G-protein activation including adenylyl cyclases, ion channels, and components of the mitogen activated protein kinase (MAPK) cascade. For example, agonist stimulation of opioid receptors leads to an inhibition of adenylyl cyclase activity and a reduction of cyclic adenosine monophosphate (cAMP) levels in the cell (Sharma et al., 1977; Chakrabarti et al., 2016) as well as a suppression of the activity of protein kinase A (Fleming et al., 1992; Zhang and Pan, 2010). In addition, the Go subunit directly interacts with G-protein inward rectifying potassium channels leading to increased hyperpolarization of the cell, and reduced cell excitability (North et al., 1987; Law et al., 2000). The dissociated Gβγ subunit is responsible for the direct blockade of calcium channels therefore reducing intracellular calcium concentrations (Moises et al., 1994), which leads to suppression neurotransmitter release.

Following removal of the opiate, the functional activity of the cAMP pathway increases continuously. These changes in the functional state of the cAMP pathway are regulated through stimulation of adenylyl cyclases and protein kinase A as a consequence of chronic administration of opiates. The phosphorylated cAMP response element (CRE)-binding protein (pCREB), and related proteins, are indicators of protein kinase A activity. Studies in male rodents indicate that CREB is essential for morphine-induced changes in gene expression precipitating reward- and withdrawal-associated behavior: opioid withdrawal upregulates cAMP by increasing adenylyl cyclase activity, leading to increased pCREB levels in reward-related brain regions.

**Sex Differences in the Neurobiological Response to Opiate Reward**

Sex-based differences in the cellular and neurobiological mechanisms underlying sex differences in the rewarding properties of opioids are poorly understood (Dahan et al., 2008; Lee and Ho, 2013; Huhn et al., 2018). Converging evidence from the reproductive and pain literatures suggests interactions among opioids, gonadal hormones, opioid receptors, and estrogen receptors may underlie sex differences in addictive responsiveness to opioid drugs (Lee and Ho, 2013). There is evidence demonstrating sex differences in the development of tolerance and dependence to morphine (Craft et al., 1999, 2004; Dahan et al., 2008). Sex differences in
the potency of morphine seem to account for differences in tolerance when animals are exposed to the same dose of morphine (Barrett et al., 2001). However, most of what is currently known about opioid dependence and withdrawal comes from studies conducted exclusively in males. Results of the few sex differences studies that have been conducted show that male rodents express a greater magnitude of withdrawal symptoms than females during spontaneous withdrawal from chronic morphine administration (Cicero et al., 2002), but not naloxone-precipitated withdrawal (Ali et al., 1995; Cicero et al., 2002). However, caution should be taken when evaluating the methods and results of these experiments and others; at this point in time, most withdrawal scales have been developed using only male animals. As such, a detailed withdrawal syndrome for the female phenotype is currently unknown.

Recently, work from our lab has begun to establish sex differences in the behavioral response and molecular signaling within the tVTA resulting from morphine withdrawal (Bobzean et al., 2019). We observed sex differences in the expression and duration of spontaneous somatic morphine withdrawal. Morphine dependent male rats displayed a more severe opiate withdrawal syndrome sooner after cessation of morphine, while females displayed a more protracted withdrawal syndrome which lasting at least 72h after termination of morphine treatment (Bobzean et al., 2019). In addition, we demonstrated a correlation between activation of CREB in the tVTA and severity of morphine withdrawal symptoms in females (Bobzean et al., 2019). Overall, these findings indicate that ovarian hormone status may influence the severity and/or persistence of symptoms and CREB expression.

Sex differences and hormonal regulation of opioid receptor binding and density as it relates to reproductive behaviors are well known. Several studies have identified sex differences and hormonal regulation of opioid receptor densities (Limonta et al., 1991; Maggi et al., 1991, 1993; Dondi et al., 1992; Piva et al., 1995), distribution, and signaling efficiency (Lee and Ho, 2013; Huhn et al., 2018). There is evidence demonstrating sex differences in the development of analgesic tolerance and dependence to morphine (Craft et al., 1999, 2004; Dahan et al., 2008). Sex differences in the potency of morphine seem to account for differences in tolerance to the antinociceptive effects of the drug when animals are exposed to the same dose of morphine (Barrett et al., 2001). Although males develop analgesic tolerance to chronic morphine administration more quickly than females, one study observed higher NAc glutamate levels in morphine-tolerant female rats (Mousavi et al., 2007). Increased glutamate in NAc induces tolerance by downregulating glutamate transporters (Yang et al., 2008).

In summary, studies of sex differences in opioid withdrawal are severely lacking, and the few that do exist report inconsistent results: male rodents express greater somatic symptoms of opioid withdrawal than females (Cicero et al., 2002; Towers et al., 2019); females are more sensitive than males (Ali et al., 1995; Papaleo and Contarino, 2006); no sex differences, or females more severely affected after acute morphine administration or naloxone-precipitated withdrawal (el-Kadi and Sharifi, 1994; Ali et al., 1995; Craft et al., 1999; Cicero et al., 2002; Papaleo and Contarino, 2006; Bodnar and Kest, 2010). Aside from methodological differences (i.e., drug dose, exposure frequency/duration, withdrawal sign measured, etc.), these inconsistencies may be due, in part, to lack of assessment of estrous cycle phase in females (Bobzean et al., 2014b; Becker and Chartoff, 2019). Currently, most of what is currently known about opioid withdrawal has been derived from studies exclusively in males and then extrapolated to females as most withdrawal scales have been developed using male subjects (Ariken et al., 2001; Puigdollers et al., 2004). The dearth of studies characterizing opioid withdrawal in females is surprising, given reports that sex and ovarian hormone activity modulate pain sensitivity (Berkley, 1997; Gureje et al., 1998; Stoffel et al., 2003; Fillingim et al., 2009; Green et al., 2009; Mogil, 2012), pain inhibition (Negus et al., 2002; Craft, 2003; Stoffel et al., 2003), nociception processing/opioid analgesia (Mogil, 2012; Amandusson and Blomqvist, 2013), and sensitivity to stress (Hodes, 2018), all variables known to promote opioid use.

**SUMMARY**

The evidence identifying important differences in the patterns of drug use, abuse, and addiction between men and women implicates sex as a risk factor for developing substance use disorder and as a powerful component affecting the course of treatment. Sex differences and sensitivity to gonadal hormones within the structure and functions of the mesolimbic reward system are linked to sex differences in the neurobehavioral response to drugs of abuse. It has also been demonstrated that the underlying cause of these sex differences on DA signaling is the cyclic fluctuation in E2 levels and its downstream neurobiological effects.

The overarching goal of much of the work reviewed in this paper is to determine how hormonal cycles affect the development of addictive phenotypes. Beginning in the 1990s studies identified estrous cycle effects on DA release and uptake in the NAc and DS (Thompson and Moss, 1994; Xiao and Becker, 1994; Thompson and Moss, 1997; Cecconi et al., 2004). Since then, data have showed that striatal DA release is increased during estrous cycle phases associated with high levels of E2 (Yoest et al., 2018). Moreover, DA clearance is shown to be substantially lower during these same phases of the cycle and higher during phases with low levels of circulating E2 (Yoest et al., 2018). In addition, basal firing rates of DA neurons of the VTA vary during the different phases of the rodent estrous cycle: DA firing rates are highest in estrus, lowest in proestrus, and intermediate in diestrus (Zhang et al., 2008). More recent work, has confirmed and extended these findings by demonstrating high levels of E2 enhance DAergic responses to cocaine and cocaine-associated rewarding cues (Calipari et al., 2017). This, in turn, leads to increased VTA-NAc responses to the drug-associated cues alone even at later stages of the cycle (Calipari et al., 2017). Moreover, cues paired with cocaine during estrus
results in greater activation of striatal brain regions (Johnson et al., 2019). Taken all together, these data demonstrate a potential mechanism by which drug-induced potentiation of the activity of DA projections from the VTA to the NAc during estrus could motivate self-administration behavior and increased responsiveness to drug-associated cues during other phases of the cycle.

Over 30 years of research has established that cyclic fluctuations of E2 modulate the mesolimbic reward. Parallel research demonstrates that mesolimbic reward pathways become dysregulated under states of chronic drug use. As these two areas of research converge, it becomes readily apparent that fluctuations in levels of E2 over the hormonal cycle of the female likely modulate the drug-induced dysregulation of the mesolimbic DA reward pathway over the course of individual's drug-taking career. Therefore, when considering sex differences in addiction, it is critical to consider female hormonal cycles.

REFERENCES

Alexander, R. K., Coombs, R. B., and Hadaway, P. F. (1978). The effect of housing and gender on morphine self-administration in rats. Psychopharmacology 58, 175–179. doi: 10.1007/bf00246903

Ali, B. H., Sharif, S. I., and Elkadi, A. (1995). Sex differences and the effect of gonadectomy on morphine-induced antinociception and dependence in rats and mice. Clin. Exp. Pharmacol. Physiol. 22, 342–344. doi: 10.1111/j.1440-1681.1995.tb02012.x

Almey, A., Filardo, E. J., Milner, T. A., and Brake, W. G. (2012). Estrogen receptors are found in glia and at extranuclear neuronal sites in the dorsal striatum of female rats: evidence for cholinergic but not dopaminergic colocalization. Endocrinology 153, 5373–5383. doi: 10.1210/en.2012-1458

Almey, A., Milner, T. A., and Brake, W. G. (2015). Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females. Horm. Behav. 74, 125–138. doi: 10.1016/j.yhbeh.2015.06.010

Almey, A., Milner, T. A., and Brake, W. G. (2016). Estrogen receptor alpha and G-protein coupled estrogen receptor 1 are localized to GABAergic neurons in the dorsal striatum. Neurosci. Lett. 622, 118–123. doi: 10.1016/j.neulet.2016.04.023

Alyea, R. A., and Watson, C. S. (2009). Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux. BMC Neurosci. 10:59. doi: 10.1186/1471-2202-10-59

Ahammaduson, A., and Blomqvist, A. (2013). Estrogenic influences in pain processing. Front. Neuroendocrinol. 34, 329–349. doi: 10.1016/j.yfrne.2013.06.001 doi: 10.1016/j.yfrne.2013.06.001

Anderson, S. M., and Pierce, R. C. (2005). Cocaine-induced alterations in dopamine receptor signaling: implications for reinforcement and reinstatement. Pharmacol. Ther. 106, 389–403. doi: 10.1016/j.pharmthera.2004.12.004

Ang, E., Chen, J., Zagouras, P., Magna, H., Holland, J., Schaeffer, E., et al. (2001). Induction of nuclear factor-κB in nucleus accumbens by chronic cocaine and prescription opioids: strategies and methods for research on sex differences in brain and behavior. Neuropsychopharmacology 146, 1650–1673.

Back, S. E., Payne, R. L., Simpson, A. N., and Brady, K. T. (2010). Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict. Behav. 35, 1001–1007. doi: 10.1016/j.addbeh.2010.06.018

Back, J. B. (2016). Sex differences in addiction. Psychopharmacology 233, 3143–3145. doi: 10.1007/s00213-016-4602-2

Back, J. B. (2019). Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 211, 104209. doi: 10.1016/j.pbb.2019.104209

Back, J. B., and Chartoff, E. (2019). Sex differences in neural mechanisms mediating reward and addiction. Neurropsychopharmacology 44, 166–183. doi: 10.1038/s41386-018-0125-6

Becker, J. B., and Koob, G. F. (2016). Sex differences in animal models: focus on addiction. Pharmacol. Rev. 68, 242–263. doi: 10.1124/pr.115.011163

Becker, J. B. (1999). Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 64, 803–812. doi: 10.1016/s0091-3057(99)00168-9

Becker, J. B. (2016). Sex differences in addiction. Dialog. Clin. Neurosci. 18, 395–402.

Becker, J. B., and Chartoff, E. (2019). Sex differences in neural mechanisms mediating reward and addiction. Neurropsychopharmacology 44, 166–183. doi: 10.1038/s41386-018-0125-6

Becker, J. B., and Koob, G. F. (2016). Sex differences in animal models: focus on addiction. Pharmacol. Rev. 68, 242–263. doi: 10.1124/pr.115.011163

AUTHOR CONTRIBUTIONS

SK and LP participated in drafting various sections of the manuscript and revising it critically for important intellectual content. LP gave final approval of the version to be submitted.

FUNDING

This research was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number R15DA040809 (LP).

ACKNOWLEDGMENTS

We thank Ross J. Armant for assistance with the figures.
Bodnar, R. J., and Kest, B. (2010). Sex differences in opioid analgesia, hyperalgesia, and endogenous opiates and behavior: 2013. *Brain Res.* 120, 176–183.

Bock, R., Shin, J. H., Kaplan, A. R., Dobi, A., Markey, E., Kramer, P. F., et al. (2008). Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. *J. Neurosci.* 28, 5671–5685. doi: 10.1523/jneurosci.1039-08.2008

Boulware, M. I., Weick, J. P., Becklund, B. R., Kuo, S. P., Groth, R. D., and Mermelstein, P. G. (2005). Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. *J. Neurosci.* 25, 5066–5078. doi: 10.1523/jneurosci.1427-05.2005

Bourdery, R., Sanchez-Catalan, M. J., Kaufling, J., Balica-Pedicino, J. J., Freund-Mercier, M. J., Veinante, P., et al. (2014). Control of the nigrostriatal dopamine neuron activity and motor function by the tail of the ventral tegmental area. *Neuropsychopharmacology* 39, 2788–2798. doi: 10.1038/npp.2014.129

Brady, K. T., and Randall, C. L. (1999). Gender differences in substance use disorders. *Psychiatr. Clin. North Am.* 22, 241–252.

Branco, A., Bregman, D., Ahn, H. F., Pau, M. L., Menard, C., C annexano, V., et al. (2017). Sub-chronic variable stress induces sex-specific effects on glutamatergic synapses in the nucleus accumbens. *Neuroscience* 350, 180–189. doi: 10.1016/j.neuroscience.2017.03.014

Buchta, W. C., and Riegel, A. C. (2015). Chronic cocaine disrupts mesocortical learning mechanisms. *Brain Res.* 1628, 88–103. doi: 10.1016/j.brainres.2015.02.003

Buffalari, D. M., Baldwin, C. K., Feltenstein, M. W., and See, R. E. (2012). Corticotrophin releasing factor (CRF) induced reinstatement of cocaine seeking in male and female rats. *Physiol. Behav.* 105, 209–214. doi: 10.1016/j.physbeh.2011.08.020

Calipari, E. S., Juarez, B., Morel, C., Walker, D. M., Cahill, M. E., Ribeiro, E., et al. (2017). Dopaminergic dynamics underlying sex-specific cocaine reward. *Nat. Commun.* 8:13877.

Carlezon, W. A., Thome, J. Jr., Olson, V. G., Lane-Ladd, S. B., Brodkin, E. S., Hiroi, N., et al. (1998). Regulation of cocaine reward by CREB. *Science* 282, 2272–2275. doi: 10.1126/science.282.5397.2272

Castner, S. A., Xiao, L., and Becker, J. B. (1993). Sex differences in striatal dopamine: *in vivo* microdialysis and behavioral studies. *Brain Res.* 610, 127–134. doi: 10.1016/0006-8993(93)91225-h

Cecconi, S., Capacchietti, G., Russo, V., Berardelli, P., Mattioli, M., and Barboni, B. (2004). In vitro growth of preantral follicles isolated from cryopreserved ovine ovarian tissue. *Biol. Reprod.* 70, 12–17. doi: 10.1095/biolreprod.103.017774

Center for Behavioral Health Statistics and Quality (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15-4927, NSDUH Series H-50.

Centers for Disease Control and Prevention (2013). Prescription Painkiller Overdoses: A growing Epidemic, Especially Among Women. Atlanta, GA: Centers for Disease Control and Prevention.

Chakrabarti, S., Chang, A., Liu, N. J., and Gintzler, A. R. (2016). Chronic opioid treatment augments caveolin-1 scaffolding: relevance to stimulatory mu-opioid receptor adenyl cyclase signaling. *J. Neurochem.* 139, 737–747. doi: 10.1111/jnc.13852

Chandra, R., Lenz, J. D., Ganczar, A. M., Chaudhury, D., Schroeder, G. L., Han, M. H., et al. (2013). Optogenetic inhibition of D1R containing nucleus accumbens neurons alters cocaine-mediated regulation of Tiam1. *Front. Mol. Neurosci.* 6:13. doi: 10.3389/fnmol.2013.00013

Chen, K., and Kandel, D. (2005). Relationship between extent of cocaine use and dependence among adolescents and adults in the United States. *Drug Alcohol Depend.* 68, 65–85. doi: 10.1016/j.drugalcdep.2004.08.006-8

Ciceri, T. J., Aylward, S. C., and Meyer, E. R. (2003). Gender differences in the intravenous self-administration of mu opiate agonists. *Pharmacol. Biochem. Behav.* 74, 541–549. doi: 10.1016/s0091-3057(02)01039-0

Ciceri, T. J., Nock, B., and Meyer, E. R. (2002). Gender-linked differences in the expression of physical dependence in the rat. *Pharmacol. Biochem. Behav.* 72, 691–697. doi: 10.1016/s0091-3057(02)00740-2

Clark, D., and White, F. J. (1987). D1 dopamine receptor—the search for a phenotype. *Science* 238, 7272–7275. doi: 10.1126/science.238.4838.7272

Craft, R. M. (2003). Sex differences in opioid analgesia: 'from mouse to man'. *Clin. J. Pain* 19, 175–186. doi: 10.1097/00002508-200305000-00005

Kokane and Perrotti
Craft, R. M., Mogil, J. S., and Aloisi, A. M. (2004). Sex differences in pain and analgesia: the role of gonadal hormones. *Eur. J. Pain* 8, 397–411. doi: 10.1016/j.ejpain.2004.01.003

Craft, R. M., Stratmann, J. A., Bartok, R. E., Walpole, T. I., and King, S. J. (1999). Sex differences in development of morphine tolerance and dependence in the rat. *Psychopharmacology* 143, 1–7. doi: 10.1007/s002130050911

Creutz, L. M., and Kritzer, M. F. (2002). Estrogen receptor-beta immunoreactivity in the midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and A8 dopamine cell groups. *J. Comp. Neurol.* 446, 288–300. doi: 10.1002/cne.10207

Dahan, A., Kest, B., Waxman, A. R., and Sarton, E. (2008). Sex-specific responses to opioids: animal and human studies. *Anesth. Analg.* 107, 83–95. doi: 10.1213/an.0b013e31816b6a4a

Dunn, K. E., Weerts, E. M., Huhn, A. S., Schroeder, J. R., Tompkins, D. A., Bigelow, G. E., et al. (2018). Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. *Addict. Biol.* 23:e12680.

Eagle, A., Al Masraf, B., and Robison, A. J. (2019). “Transcriptional and epigenetic regulation of reward circuitry in drug addiction,” in *Neural Mechanisms of Addiction*, ed. M. Torregrossa (Cambridge, MA: Academic Press), 23–34. doi: 10.1016/B978-0-12-812202-0.00003-8

Engelmann, C., and Haenold, R. (2016). Transcriptional Control of Synthetic Plasticity by Transcription Factor NF-κB. *Neural Plast.* 2016:7027949.

Everitt, B. J., Parkinson, J. A., Olmstead, M. C., Arroyo, M., Robledo, P., and Robbins, T. W. (1999). Associative processes in addiction and reward. The role of amydala-ventral striatal subsystems. *Ann. N. Y. Acad. Sci.* 877, 412–438. doi: 10.1111/j.1749-6632.1999.tb09280.x

Feltenstein, M. W., Henderson, A. R., and See, R. E. (2011). Enhancement of cue-induced reinstatement of cocaine-seeking in rats by yohimbine: sex differences and the role of the estrous cycle. *Psychopharmacology* 216, 53–62. doi: 10.1007/s00213-011-2187-6

Fleming, L. M., Ponjee, G., and Childers, S. R. (1992). Inhibition of protein kinase C signaling in the hypothalamic arcuate nucleus regulates sexual receptivity in female rats. *Endocrinology* 130, 1379–1385. doi: 10.1210/jc.82.12.4258

Ford, C. P., Mark, G. P., and Williams, J. T. (2006). Properties and opioid inhibition of mesolimbic dopamine neurons. *Neuropsychopharmacology* 927–937. doi: 10.1038/npp.2014.268

Fox, H. C., Sofuoglu, M., Morgan, P. T., Tuit, K. L., and Sinha, R. (2013). The influences of sex and estrous cyclicity on conditioned cue-induced reinstatement of extinguished heroin-seeking behavior in rats. *Neurosci. Lett.* 532, 134–138. doi: 10.1016/j.s封闭式引用.2012.12.022

Fridén, J. (2000). Mechanical allodynia and neuropathic pain. *Anesthesiology* 93, 1268–1286.

Fridén, J., Apelqvist, A., Isaksson, J., and Stenberg, J. (2003). The effect of different pain stimuli on mechanical allodynia. *Anesthesiology* 99, 1251–1257. doi: 10.1097/01.ANE.0000084935.68757.11

Ford, C. P., Mark, G. P., and Williams, J. T. (2006). Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. *J. Neurosci.* 26, 2788–2797. doi: 10.1523/jneurosci.4331-05.2006

Fotor, M. H., and Woolley, C. S. (2010). Quantitative analysis of pre- and postsynaptic sex differences in the nucleus accumens. *J. Comp. Neurol.* 518, 1330–1348.

Fox, H. C., and Sinha, R. (2009). Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women. *Harr. Rev. Psychiatry* 17, 103–119. doi: 10.1007/s00291-008-0299-9

Fuchs, R. A., Evans, K. A., Mehta, R. H., Case, J. M., and See, R. E. (2005). Influence of sex and estrous cyclicity on conditioned cue-induced reinstatement of cocaine-seeking behavior in rats. *Psychopharmacology* 179, 662–672. doi: 10.1007/s00213-004-0010-7

Fuchs, R. A., and See, R. E. (2002). Basolateral amygdala inactivation abolishes conditioned stimulus- and heroin-induced reinstatement of extinguished heroin-seeking behavior in rats. *Psychopharmacology* 160, 425–433. doi: 10.1007/s00213-001-0997-7
Gallo, R. J., Crits-Christoph, P., Ten Have, T. R., Barber, J. P., Frank, A., Griffin, M. L., et al. (2007). Differential transitions between cocaine use and abstinence for men and women. J. Consult. Clin. Psychol. 75, 95–103. doi: 10.1037/0022-006X.75.1.95

Gangarossa, G., Espallergues, J., de Kerchove d’Exaerde, A., El Mestikawy, S., Gerfen, C. R., and Hervé, D. (2013). Distribution and compartmental organization of GABAergic medium-sized spiny neurons in the mouse nucleus accumbens. Front. Neural Circ. 7:222. doi: 10.3389/fncir.2013.00222

Garcia-Carmona, J. A., Baroja-Mazo, A., Milanés, M. V., and Laorden, M. L. (2015). Sex differences between CRF1 receptor deficient mice following naloxone-precipitated withdrawal in a conditioned place avoidance paradigm: implication of HPA axis. PLoS One 10:e0121125. doi: 10.1371/journal.pone.0121125

Gardner, E. L. (2011). Addiction and brain reward and antireward pathways. Adv. Psychosom. Med. 30, 22–60. doi: 10.1159/000324065

Geisler, S., and Wise, R. A. (2008). Functional implications of glutamatergic projections to the ventral tegmental area. Rev. Neurosci. 19, 227–244.

Gerfen, C. R., Engber, T. M., Mahan, L. C., Suel, Z., Chase, T. N., Monoma, F. J. Jr., et al. (1990). D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429–1432. doi: 10.1126/science.2147780

Gerfen, C. R., and Surmeier, D. J. (2011). Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441–466. doi: 10.1146/annurev-neuro-061010-113641

Gilles, G. E., and McArthur, S. (2010). Estrogen actions in the brain and the basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 29, 81–85. doi: 10.1038/sj.npp.1300301

Huang, Y., Schlüter, O. M., and Dong, Y. (2015). Silent synapses speak up: updates of the neural rejuvenation hypothesis of drug addiction. Neuroscientist 21, 451–459. doi: 10.1177/1073858415579405

Hikida, T., Kimura, K., Wada, N., Funabiki, K., and Nakanishi, S. (2010). Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron 66, 896–907. doi: 10.1016/j.neuron.2010.05.011

Hodes, G. E. (2018). A primer on sex differences in the behavioral response to stress. Curr. Opin. Behav. Sci. 23, 75–83. doi: 10.1016/j.cobeha.2018.03.012

Hruska, R. E., and Silbergeld, E. K. (1980). Estradiol treatment enhances dopamine receptor sensitivity in the rat striatum. Eur. J. Pharmacol. 61, 397–400. doi: 10.1016/0014-2999(80)90081-3

Hu, M., Crombag, H. S., Robinson, T. E., and Becker, J. B. (2004). Biological basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 29, 81–85. doi: 10.1038/sj.npp.1300301

Jhou, T. C., Xu, S. P., Lee, M. R., Gallen, C. L., and Ikemoto, S. (2012). Mapping FosB differentially modulates nucleus accumbens direct and indirect pathway organization of GABAergic medium-sized spiny neurons in the mouse nucleus accumbens. J. Neurosci. 32, 726–741. doi: 10.1210/er.2007-01964.x

Jhou, T. C., Geisler, S., Marinelli, M., Degarmo, B. A., and Zahm, D. S. (2009b). 66, 896–907. doi: 10.1016/j.neuron.2010.05.011

Johnson, S. W., and North, R. A. (1992a). Opioids excite dopamine neurons by

Kane, W. A., Zhao, L., Li, J. C., and Ikemoto, S. (2017). FosB induction regulates nucleus accumbens-olfactory tubercle dopamine neuron activity. J. Comp. Neurol. 525, 803–819. doi: 10.1002/cne.24710

Kanazawa, K., Tanaka, N., and Kawamura, A. (1992). Estradiol modulates activity of dopaminergic neurons in the ventral midbrain of the rat. Brain Res. 56, 27–284. doi: 10.1016/j.brainres.2007.05.004

Kheirbek, M. A., and Hyman, S. E. (2001). The ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 36, 177–188. doi: 10.1016/j.brainresrev.2000.12.001
Johnson, S. W., and North, R. A. (1992b). Two types of neuron in the rat ventral tegmental area and their synaptic inputs. J. Physiol. 450, 455–468. doi: 10.1113/jphysiol.1992.sp019136

Kavalis, P. W., and McFarland, K. (2003). Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 168, 44–56. doi: 10.1007/s00213-007-0815-y

Kano, T., Suzuki, Y., Shibuya, M., Kiuchi, K., and Hagiwara, M. (1995). Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice. Neuroreport 6, 2197–2200. doi: 10.1097/00001756-199511000-00023

Karami, M., and Zarrindast, M. R. (2008). Morphine sex-dependently induced place conditioning in adult Wistar rats. Eur. J. Pharmacol. 582, 78–87. doi: 10.1016/j.ejphar.2007.12.010

Kauer, J. A., and Malenka, R. C. (2007). Synaptic plasticity and addiction. Nat. Rev. Neurosci. 8, 844–858

Kaufling, J., and Aston-Jones, G. (2015). Persistent Adaptations in Afferents to Ventral Tegmental Dopamine Neurons after Opiate Withdrawal. J. Neurosci. 35, 10290–10303. doi: 10.1523/jneurosci.0715-15.2015

Kelly, M. J., and Ronnekleiv, O. K. (2008). Membrane-initiated estrogen signaling in hypothalamic neurons. Mol. Cell. Endocrinol. 290, 14–23. doi: 10.1016/j.mce.2008.04.014

Kokane, S. S., Hoch, A. C., and Perrotti, L. I. (2019). Sex Differences in Cocaine Reward and Estradiol-Mediated Hypersensitivity to Cocaine Cues are Associated with Changes in ERK Activity within the Mesolimbic Reward Pathway. Chicago, IL: Society for Neurosciences.

Koo, J. W., Mazzi-Robinson, M. S., Chaudhury, D., Juarez, B., LaPlant, Q., Ferguson, D., et al. (2012). BDNF is a negative modulator of morphine action. Science 338, 124–128. doi: 10.1126/science.122265

Koob, G. F., and Le Moal, M. (2008). Addiction and the brain reward system. Annu. Rev. Psychol. 59, 29–53. doi: 10.1146/annurev.psych.59.103006.093548

Koob, G. F., Sanna, P. P., and Bloom, F. E. (1998). Neuroscience of addiction. Neuron 21, 467–476.

Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction. Neuronpsychopharmacology 35, 217–238.

Koob, G. F., and Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3, 760–773. doi: 10.1016/s2215-0366(16)00104-8

Koos, T., and Tepper, J. M. (1999). Inhibitory control of neostriatal projection neurons by GABAergic interneurons. J. Neurosci. 19, 1143–1162. doi: 10.1152/jn.00264.2019

Krentzel, A. A., Barrett, L. R., and Meitzen, J. (2019). Estradiol rapidly modulates inhibitory inputs from rostromedial tegmental neurons to regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. Neuryspsychopharmacology 37, 1164–1176. doi: 10.1038/npp.2011.302

Lee, C. W., and Ho, I. K. (2013). Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors. Mol. Pain 9:45.

Lemberger, T., Parkitna, J. R., Chai, M., Schultz, G., and Engblom, D. (2008). CREB has a context-dependent role in activity-regulated transcription and maintains neuronal cholesterol homeostasis. FASEB J. 22, 2872–2879. doi: 10.1096/fj.08-107888

Lenz, J. D., and Lobo, M. K. (2013). Optogenetic insights into striatal function and behavior. Behav. Brain Res. 235, 44–54. doi: 10.1016/j.bbr.2013.04.018

Lester, J., Fink, S., Aronin, N., and DiFiglia, M. (1993). Colocalization of D1 and D2 dopamine receptor mRNAs in striatal neurons. Brain Res. 621, 106–110. doi: 10.1016/0006-8993(93)90303-5

Levesque, D., and Di Paolo, T. (1988). Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17 beta-estradiol. Neurosci. Lett. 88, 113–118. doi: 10.1016/0304-3908(88)90324-2

Levesque, D., and Di Paolo, T. (1989). Chronic estradiol treatment increases ovariectomized rat striatal D-1 dopamine receptors. Life Sci. 45, 1813–1820. doi: 10.1016/0024-3205(89)90522-5

Limonta, P., Dondi, D., Maggi, R., and Piva, F. (1991). Testosterone and postnatal ontogenesis of hypothalamic mu [(3)H]dihydromorphine) opioid receptors in the rat. Brain Res. Dev. Brain Res. 62, 131–136. doi: 10.1016/0165-3806(91)90780-r

Lobo, D. S., and Kennedy, J. L. (2006). The genetics of gambling and behavioral addictions. CNS Spectr. 11, 931–939. doi: 10.1017/s1092852900015121

Lobo, M. K., Covington, H. E., Chaudhury, D. III, Friedman, A. K., Sun, H., Damez-Werno, D., et al. (2010). Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 330, 385–390. doi: 10.1126/science.1188472

Lobo, M. K., and Nestler, E. J. (2011). The striatal balancing act in drug addiction: Gonadectomy but not biological sex affects burst-firing in dopamine neurons of the ventral tegmental area and in prefrontal cortical neurons projecting to the ventral tegmentum in adult rats. Eur. J. Neurosci. 45, 106–120. doi: 10.1111/j.1460-9568.2011.07380.x

Locklear, M. N., Michaelos, M., Collins, W. F., and Kritzer, M. F. (2017). Gonadectomy but not biological sex affects burst-firing in dopamine neurons of the ventral tegmental area and in prefrontal cortical neurons projecting to the ventral tegmentum in adult rats. Eur. J. Neurosci. 45, 106–120. doi: 10.1111/j.1460-9568.2011.07380.x

Lockner, M. N., Ericson, M., Stomberg, R., and Soderpalm, B. (2007). Characterization of ethanol-induced dopamine elevation in the rat nucleus accumbens. Eur. J. Pharmacol. 555, 148–155. doi: 10.1016/j.ejphar.2006.10.055
Lynch, W. J., and Carroll, M. E. (1999). Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats. Psychopharmacology 144, 77–82. doi: 10.1007/s002130050979

Lynch, W. J., and Carroll, M. E. (2000). Reinstatement of cocaine self-administration in rats: sex differences. Psychopharmacology 148, 196–200. doi: 10.1007/s002130050042

Lynch, W. J., Kiraly, D. D., Caldarone, B. J., Picciotto, M. R., and Taylor, J. R. (2007). Effect of cocaine self-administration on striatal PKA-regulated signaling in male and female rats. Psychopharmacology 191, 263–271. doi: 10.1007/s00213-006-0656-0

Lynch, W. J., Roth, M. E., Mickelberg, J. L., and Carroll, M. E. (2001). Role of estrogen in the acquisition of intravenously self-administered cocaine in female rats. Pharmacol. Biochem. Behav. 68, 641–646. doi: 10.1016/s0091-3057(01)00455-5

Lynch, W. J., and Taylor, J. R. (2004). Sex differences in the behavioral effects of 24-h/day access to cocaine under a discrete trial procedure. Neuropharmacology 29, 943–951. doi: 10.1016/j.nphs.1300389

Lynch, W. J., and Taylor, I. R. (2005). Decreased motivation following cocaine self-administration under extended access conditions: effects of sex and ovarian hormones. Neuropharmacology 30, 927–935. doi: 10.1016/j.nphs.1300656

Madhavan, A., Bonci, A., and Whistler, J. L. (2010). Opioid-Induced GABA potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area. J. Neurosci. 30, 14029–14035. doi: 10.1523/jneurosci.21-21-08655.2001

Meitzen, J., Pflepsen, K. R., Stern, C. M., Meisel, R. L., and Mermelstein, P. G. (2013). Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci. 16, 595–604. doi: 10.1523/jneurosci.16-02-00595.1996

Mermelstein, P. G., and Micevych, P. E. (2008). Nervous system physiology regulated by membrane estrogen receptors. Rev. Neurosci. 19, 413–424.

Mhayer, A. J., and Dorsa, D. M. (2006). Estrogen activates rapid signaling in the brain: role of estrogen receptor alpha and estrogen receptor beta in neurons and glia. Neuroscience 138, 851–858. doi: 10.1016/j.neuroscience.2005.10.019

Micevych, P. E., and Mermelstein, P. G. (2008). Membrane estrogen receptors acting through metabolic glutamate receptors: an emerging mechanism of estrogen action in brain. Mol. Neurobiol. 38, 66–77. doi: 10.1007/s12053-008-0834-z

Miller, J. C. (1983). Sex differences in dopaminergic and cholinergic activity and function in the nigro-striatal system of the rat. Psychoneuroendocrinology 8, 225–236. doi: 10.1016/0306-4533(83)90059-8

Milner, T. A., Thompson, L. I., Wang, G., Kivets, J. A., Martin, E., Zhou, P., et al. (2010). Distribution of estrogen receptor beta containing cells in the brains of bacterial artificial chromosome transgenic mice. Brain Res. 1351, 74–96. doi: 10.1016/j.brainres.2010.06.038

Mirbaha, H., Tabaezadeh, M., Shaterian-Mohammadi, H., Tahsili-Fahadan, P., and Dephour, A. R. (2009). Estrogen pretreatment modulates morphine-induced conditioned place preference in ovariectomized mice. Pharmacol. Biochem. Behav. 92, 399–403. doi: 10.1016/j.pbb.2009.01.009

Mogil, J. S. (2012). Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat. Rev. Neurosci. 13, 859–866. doi: 10.1038/nrn3360

Moises, H. C., Rusin, K. L., and Macdonald, R. L. (1994). Mu- and kappa-opioid receptors selectively reduce the same transient components of high-threshold calcium current in rat dorsal root ganglion sensory neurons. J. Neurosci. 14, 5903–5916. doi: 10.1523/jneurosci.14-10-05903.1994

Morissette, M., Biron, D., and Di Paolo, T. (1990). Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res. Bull. 25, 419–422. doi: 10.1016/0361-9230(90)90231-n

Morissette, M., Le Saux, M. D., Astous, M., Jourdain, S., Al Swedi, S., Morin, N., et al. (2008). Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J. Steroid Biochem. Mol. Biol. 108, 327–338. doi: 10.1016/j.jsbmb.2007.09.011

Mortensen, O. V., and Amara, S. G. (2003). Dynamic regulation of the dopamine transporter. Eur. J. Pharmacol. 479, 159–170. doi: 10.1016/j.ejphar.2003.08.066

Mousavi, Z., Shafagh, B., Kobarfard, F., and Jorjani, M. (2007). Sex differences and role of gonadal hormones on glutamate level in the nucleus accumbens in morphine tolerant rats: a microdialysis study. Eur. J. Pharmacol. 578, 637–647. doi: 10.1016/j.ejphar.2007.09.066

Murphy, D. D., and Segal, M. (1997). Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc. Natl. Acad. Sci. U.S.A. 94, 1482–1487. doi: 10.1073/pnas.94.4.1482

Nazarian, A., Sun, W. L., Zhou, L., Kemen, L. M., Jenab, S., and Quinones-Janib, V. (2009). Sex differences in basal and cocaine-induced alterations in PKA and CREB proteins in the nucleus accumbens. Psychopharmacology 203, 641–650. doi: 10.1007/s00213-008-1141-5

Negus, S. S., Zuzga, D. S., and Mello, N. K. (2002). Sex differences in opioid antinoceptive in rhesus monkeys: antagonism of fentanyl and U50,488 by quadoxazine. J. Pain 3, 218–226. doi: 10.1016/s1351-735X(01)00124-1

Nestler, E. J. (2001). Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119–128. doi: 10.1038/35053570

Nestler, E. J. (2002). Common molecular and cellular substrates of addiction and memory. Neurobiol. Learn. Mem. 78, 637–647. doi: 10.1016/s0741-3071(02)00841-0

Nestler, E. J. (2008). Review. Transcriptional mechanisms of addiction: role of DeltaFosB. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3245–3255. doi: 10.1098/rstb.2008.0067

Meredith, G. E., Baldo, B. A., Andrezejewski, M. E., and Kelley, A. E. (2008). The structural basis for mapping behavior onto the ventral striatum and its subdivisions. Brain Struct. Funct. 213, 17–27. doi: 10.1007/s00429-008-0175-3

Mermelstein, P. G. (2009). Membrane-localised oestrogen receptor alpha and beta influence neuronal activity through activation of metabolic glutamate receptors. J. Neuroendocrinol. 21, 257–262. doi: 10.1111/j.1365-2826.2009.01838.x
Nestler, E. J. (2016). Reflections on: “A general role for adaptations in G-Proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function”. Brain Res. 1645, 71–74. doi: 10.1016/j.brainres.2015.12.039

Nilsson, S., Makela, S., Treuter, E., Tuigaue, M., Thomsen, J., Andersson, G., et al. (2001). Mechanisms of estrogen action. Physiol. Rev. 81, 1535–1553.

North, R. A., Williams, J. T., Surprenant, A., and Christie, M. J. (1987). Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc. Natl. Acad. Sci. U.S.A. 84, 5487–5491. doi: 10.1073/pnas.84.15.5487

Nye, H. E., Hope, B. T., Kelz, M. B., Iadarola, M., and Nestler, E. J. (1995). Rapid expression of spontaneous somatic opiate withdrawal in mice. Brain Res. 1520, 121–133. doi: 10.1016/0006-8993(95)90281-3

O’Brien, C. P., Childress, A. R., McLellan, T., and Ehrman, R. (1990). Integrating systemic cue exposure with standard treatment in recovering drug dependent patients. Addict. Behav. 15, 355–365. doi: 10.1016/0306-4603(90)90054-y

Papaleo, F., and Contarino, A. (2006). Gender- and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice. Behav. Brain Res. 170, 110–118. doi: 10.1016/j.bbr.2005.02.009

Pasqualini, C., Olivier, V., Guibert, B., Frain, O., and Leviel, V. (1996). Rapid stimulation of striatal dopamine synthesis by estradiol. Cell Mol. Neurobiol. 16, 411–415. doi: 10.1007/BF02088105

Paulozzi, L. J., Jones, C. M., Mack, K. A., and Rudd, R. A. (2011). Vital Signs: Gonadal hormones differentially modulate cocaine-induced conditioned place preference expression. Brain Res. 1520, 121–133. doi: 10.1016/0006-8993(95)90281-3

Peterson, B. M., Martinez, L. A., Meisel, R. L., and Mermelstein, P. G. (2016). Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [H]dopamine release. Brain Res. 566, 255–264. doi: 10.1016/j.brainres.2006.06.006

Perreault, M. L., Hasbi, A. O., Dowd, B. F., and George, S. R. (2011). The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia. Front. Neuroanat. 5:31. doi: 10.3389/fnana.2011.00031

Perrotti, L. I., Bolanos, C. A., Choi, K. H., Russo, S. J., Edwards, S., Ulery, P. G., et al. (2005). DeltaFosB accumulates in a GABAergic cell population in the posterior tail of the ventral tegmental area after psychostimulant treatment. Eur. J. Neurosci. 21, 2817–2824. doi: 10.1111/j.1460-9568.2005.04110.x

Perrotti, L. I., Weaver, R. R., Robson, B., Renthall, W., Maze, I., and Vadzani, S., et al. (2008). Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse 62, 358–369. doi: 10.1002/syn.20500

Petric, J., Decembre, N., Coleman-Hardee, M. L., and Simpkins, J. W. (1991). Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [H]dopamine release. Brain Res. 566, 255–264. doi: 10.1016/s0006-8993(01)80077-8

Pollak, O. K., Malyala, A., and Kelly, M. J. (2007). Membrane-initiated signaling of estrogen in the brain. Semin. Reprod. Med. 25, 165–177. doi: 10.1055/s-2007-973429

Rincon-Cortes, M., and Grace, A. A. (2002). Dopamine-mediated modulation of odour-evoked amygdala potentials during pavlovian conditioning. Nature 417, 282–287. doi: 10.1038/417282a

Roth, M. E., and Carroll, M. E. (2004). Sex differences in the escalation of intravenous cocaine intake following long- or short-access to cocaine self-administration. Pharmacol. Biochem. Behav. 78, 199–207. doi: 10.1016/j.pbb.2004.03.018

Roth, M. E., Casimir, A. G., and Carroll, M. E. (2002). Influence of estrogen in the acquisition of intravenously self-administered heroin in female rats. Pharmacol. Biochem. Behav. 72, 313–318. doi: 10.1016/s0091-3057(01)00777-8

Russo, S. J., Bolanos, C. A., Theobald, D. E., DeCarolis, N. A., Renthall, W., and Kumar, A. (2007). IRS2: Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat. Neurosci. 10, 93–99. doi: 10.1038/nn1812

Russo, S. J., Festa, E. A., and Grace, A. A. (2003). Gonadal hormones differentially modulate cocaine-induced conditioned place preference in male and female rats. Neuroscience 120, 523–533. doi: 10.1016/s0366-6522(03)00317-8

Russo, S. J., and Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609–625. doi: 10.1038/nrn3381

Schultz, K. N., von Esenwein, S. A., Hu, M., Bennett, A. L., Kennedy, R. T., and Musatov, S. (2009). Viral vector-mediated overexpression of estrogen receptor-alpha in striatum enhances the estradiol-induced motor activity in female rats and estradiol-modulated GABA release. J. Neurosci. 29, 3529–3537. doi: 10.1523/jneurosci.6173-08.2009

Schofield, M. D., Hemsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A., et al. (2016). The nucleus accumbens: mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis. Pharmacol. Rev. 68, 816–871. doi: 10.1124/pr.116.012484

Pigidollers, E., Domingo-Salvany, A., Brugal, M. T., Torrens, M., Alvaro, J., Castillo, C., et al. (2004). Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst. Use Misuse 39, 1353–1368. doi: 10.1081/j-120039392
Yin, H. H., Knowlton, B. J., and Balleine, B. W. (2004). Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental conditioning. Eur. J. Neurosci. 19, 181–189. doi: 10.1111/j.1460-9568.2004.03995.x

Yin, H. H., Knowlton, B. J., and Balleine, B. W. (2005). Blockade of NMDA receptors in the dorsomedial striatum prevents action-outcome learning in instrumental conditioning. Eur. J. Neurosci. 22, 505–512. doi: 10.1111/j.1460-9568.2005.04219.x

Yin, H. H., Knowlton, B. J., and Balleine, B. W. (2006). Inactivation of dorsolateral striatum enhances sensitivity to changes in the action-outcome contingency in instrumental conditioning. Behav. Brain Res. 166, 189–196. doi: 10.1016/j.bbr.2005.07.012

Yoest, K. E., Cummings, J. A., and Becker, J. B. (2014). Estradiol, dopamine and motivation. Cent. Nerv. Syst. Agents Med. Chem. 14, 83–89. doi: 10.2174/187152491466141226103135

Yoest, K. E., Quigley, J. A., and Becker, J. B. (2018). Rapid effects of ovarian hormones in dorsal striatum and nucleus accumbens. Horm. Behav. 104, 119–129. doi: 10.1016/j.yhbeh.2018.04.002

Zahm, D. S., and Brog, J. S. (1992). On the significance of subterritories in the “accumbens” part of the rat ventral striatum. Neuroscience 50, 751–767. doi: 10.1016/0036-4522(92)90202-d

Zahm, D. S., and Heimer, L. (1993). Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J. Comp. Neurol. 327, 220–232. doi: 10.1002/cne.903270205

Zakharova, E., Wade, D., and Izenwasser, S. (2009). Sensitivity to cocaine conditioned reward depends on sex and age. Pharmacol. Biochem. Behav. 92, 131–134. doi: 10.1016/j.pbb.2008.11.002

Zhang, D., Yang, S., Yang, C., Jin, G., and Zhen, X. (2008). Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine. Psychopharmacology 199, 625–635. doi: 10.1007/s00213-008-1188-6

Zhang, Z., and Pan, Z. Z. (2010). Synaptic mechanism for functional synergism between delta- and mu-opioid receptors. J. Neurosci. 30, 4735–4745. doi: 10.1523/jneurosci.5968-09.2010

Zhou, Y., Watters, J. J., and Dorsa, D. M. (1996). Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 137, 2163–2166. doi: 10.1210/endo.137.5.861

Zhu, J., and Reith, M. E. (2008). Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol. Disord. Drug Targets 7, 393–409. doi: 10.2174/187152708786927877

Zorrilla, E. P., and Koob, G. F. (2019). Impulsivity derived from the dark side: neurocircuits that contribute to negative urgency. Front. Behav. Neurosci. 13:136. doi: 10.3389/fnbeh.2019.00136

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kokane and Perrotti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.